Large net loss pushes Hims & Hers Health stock down 3.56%

Traders Union
All News
Financial News
Hims & Hers Health slides 3.56% today

Highlights

Hims & Hers Health reported a net loss of $92.1 million and missed both EPS and revenue consensus for the quarter.
A $33 million restructuring charge from a shift in weight-loss drugs and partnership with Novo Nordisk drove increased near-term expenses.
Shares exhibit high volatility and persistent selling pressure, with technical signals biased bearish and expected to trade between $22.00 and $26.00 near-term.

Restructuring costs and earnings miss drive valuation reset

Hims & Hers Health reported a net loss of $92.1 million for the first quarter, marking a substantial decline compared to net income of $49.5 million in the prior year. The company also missed Wall Street expectations, recording a loss per share of $0.40 and revenue of $608.1 million, with both figures falling short of consensus estimates. Restructuring charges of about $33 million, linked to a strategic shift in weight-loss drugs and its partnership with Novo Nordisk, added to near-term costs, while subscriber growth of 9% year-over-year suggests underlying demand continues. Recent results have driven a reassessment of the company's valuation amid broad selling pressure.

Support at MA-50 holds as mixed signals and volatility persist

Technically, HIMS is trading below the MA-20 of $27.76 and the MA-200 at $36.23, but just above the MA-50 at $23.82, indicating a potential support level in the medium term. The Ichimoku Kijun sits at $25.41, establishing immediate resistance for the stock. On the daily timeframe, momentum indicators are mixed: the MACD points to strong upside potential, while the ADX signals only modest trend strength. Meanwhile, the RSI is at 45.17, Stoch RSI is at 0.00, and the CCI is at -172.5, each indicating oversold conditions. The BBP at -1.97 highlights seller dominance intraday, and the Awesome Oscillator remains neutral. Price action reflects a downside opening gap, and the stock is trading near session lows with persistently high volatility.

Downside risk dominates as resistance caps rangebound outlook

In the near term, HIMS is expected to fluctuate within a $22.00 to $26.00 volatility band relative to current levels. There is a low probability, estimated at less than 20%, of a sustained upward move. The prevailing signals suggest further downside risk is more likely. The baseline scenario assumes rangebound trading below immediate resistance at the Kijun level of $25.41; a breakout above this resistance could bring a test of $26.00, while a drop below $23.00 might expose the $22.00 support level.

Anton Kharitonov, expert at Traders Union, sees Hims & Hers Health under pressure after missing both revenue and earnings estimates and posting a major year-over-year net loss. He notes that technical signals remain sharply negative, with the stock trading below key moving averages and showing several classic signs of being oversold. Kharitonov believes further downside risk outweighs short-term recovery prospects, despite moderate subscriber growth. "Base case remains rangebound price action below $25.41; unless HIMS reclaims that resistance, downside risk toward $22.00 persists."

Earlier, analysts noted that Hims & Hers Health was likely to remain rangebound as mixed technical signals and operational headwinds limited momentum for a sustained move. The latest price action and deepening oversold conditions reinforce this cautious stance, with immediate attention on whether support near $23.00 can hold amid continued volatility.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.